Home > News > Veristat supports antibe therapeutics

1 min read

Veristat Supports Antibe Therapeutics for Pain and Inflammation Study

Clinical Trials Success Stories Regulatory Consulting Strategic Consulting Clinical Operations/Monitoring Data Management Statistics and Programming

Upon receiving approval from Health Canada, Antibe Therapeutics selected Veristat to immediately begin work on part one of a Phase 2B dose-ranging, efficacy study for their lead drug candidate ATB-346.   The study will run in Canada and is expected to conclude in December 2018.

“Veristat is excited to continue our support of Antibe Therapeutics’ ATB-346 program. We are providing full-service clinical support for Antibe’s current and upcoming Phase II dose-ranging efficacy studies,” said Shaheen Limbada, SVP Global Clinical Operations at Veristat, “We look forward to strengthening our long-term partnership with Antibe with continued support of their clinical development programs.”


Veristat’s full-service clinical development solutions are ideal for emerging and small to mid-size biopharmaceutical companies.    We deliver uncompromised value and impact to our clients as we guide them from early phase trial planning and design, through to trial execution, regulatory submission support through to post-approval.  

Read the full Antibe Therapeutics press release on the Antibe Therapeutics website.

 

 

Explore Key Related Services

2 min read

Connect with Veristat at Bio International Convention 2026

Jun 15, 2026  Veristat Events

June 22-25, 2026 – San Diego, CA

🌎 Bringing the Global Biopharma Community Together

We’re delighted to be attending...

2 min read

Connect with Veristat at DIA 2026

Jun 5, 2026  Veristat Events

June 14-18, 2026 – Philadelphia, PA

Veristat is excited to join industry leaders and innovators at the DIA 2026 Global...